1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–30
2.Bourgin C, Saidani M, Poupon C, Cauchois A, Foucher F, Leveque J, Lavoue V. Endometrial cancer in elderly women: Which disease, which surgical management?. A systematic review of the literature. Eur J Surg Oncol. 2016; 42: 166-75.
3. Dumas L, Ring A, Butler J, Kalsi T, Harari D, Banerjee S. Improving outcomes for older women with gynaecological malignancies. Cancer Treat Rev. 2016;50:99-108.
4. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (suppl 6):vi33-38.
5.. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2013;93: 468-674.
6. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120:383–397.
7.. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA. Cancer J Clin. 2013;63:11–30.
8. Buchanan EM, Weinstein LC, Hillson C. Endometrial cancer. Am Fam Physician. 2009: 80:1075–1080.
9. Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. BMJ. 2011;343:d3954.
10. Boruban MC, Altundag K, Kilic GS, Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev. 208;17:133-138.
11. MacDonald PC, Madden JD, Brenner PF,Wilson JD, Siiteri PK. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab. 1979;49:905–916.
12. Bulun SE, Economos K, Miller D, Simpson ER. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab. 1994;79:1831–1834.
13. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973; 36:207–214.
14. Department of Health. The NHS cancer plan: A plan for investment, A plan for reform. Department of Health, London; 2000.
15. Fayers P, Bottomley A. EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38(Supple 4):S125-133.
16. World Health Organization. WHO handbook for reporting results of cancer treatments. Geneva; 1979.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73: 13–22.
18. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T . ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer.2003; 98:1802-1810.
19. Bogliolo S, Gardella B, Dominoni M, Musacchi V, Cassani C, Zanellini F, De Silvestri A, Gaggero CR, Babilonti L, Spinillo A. Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. Arch Gynecol Obstet. 2016; 293:701-708.
20. Gao C, Wang Y, Tian W, Zhu Y, Xue F. The therapeutic significance of aromatase inhibitors in endometrial carcinoma. Gynecol Oncol. 2014; 134: 190-195.
21. Thangavelu A, Hewitt MJ, Quinton ND, Duffy SR. Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. Gynecol Oncol. 2013;131:613-618.
22. Valenzano Menada M, Costantini S, Moioli M, Bogliolo S, Papadia A, Ferrero S, Dugnani MC. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. Breast. 2008;17: 631-636.
23. Weis J, Wirtz MA, Tomaszewski KA, Hammerlid E , Arraras JI , Conroy T, Lanceley A , Schmidt H, Singer S , Pinto M , El-Din MA, Compter I, Holzner B , Hofmeister D, Chie WC, Harle A, Flechtner HH, Bottomley A. EORTC Quality of Life Group. Sensitivity to Change of the EORTC Quality of Life Module Measuring Cancer-Related Fatigue (EORTC QlQ-Fa12): Results From the International Psychometric Validation. Psychooncology. 2019;28:1753-1761.
24. Jing MJ, Wang JJ, Lin WQ, Lei YX, Wang PX. A Community-Based Cross-Sectional Study of
33. Caldwell G, Ragupathy K. Mirenas against malignancy: an alternative to operative management. J Obstet Gynaecol. 2018:38:731.
25. Yu Song J, Fraser IS. Effects of progestangens on human endometrium. Obstet Gynecol Sur. 1995;50:385-394.
26. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14: 357-361.
27. Podczaski E, Mortel. Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol. 2001;15: 469-489.
28. Garrett A, Quinn MA. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol. 2008;22:407-421